April 2017

Investing into Innovation to End Malaria for Good

Through a concerted effort of both public and private institutions malaria incidence has been reduced by 21 percent between 2010 and 2015, with death rates falling by 29 percent in the same period.

In Africa, where the disease remains heavily concentrated, vector control has been responsible for preventing almost 80 percent of the total cases averted. However it is widely accepted that these advances are under threat from insecticide resistance to vector control solutions.

Focused on the future and committed to address emerging challenges, Bayer is investing in the development of new ways to address insecticide resistance with long-term viability. Fludora™ Fusion, for indoor residual spraying (IRS), is the first two-way combination product for IRS, which also introduces a new mode of action. Currently in field trials across more than a ten countries, the solution is showing excellent effectiveness against resistant mosquitoes. Submitted to the WHO Pesticides Evaluation Scheme (WHOPES) in October 2015, Bayer expects to have it available for use in 2018.